Dr. Andrew Geall is the Chief Development Officer at Replicate Bioscience and cofounder of the company. Dr. Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of mRNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions. Prior to joining Replicate, Dr. Geall was Chief Scientific Officer at Precision NanoSystems Inc. (1 year). He has also held positions as Vice President of Formulations, Analytics and Chemistry at Avidity Biosciences (5 years), where he helped pioneered the development of their antibody-oligonucleotide conjugate delivery platform. Prior to Avidity, he led the mRNA vaccines Platform in the Vaccine division of Novartis (7 years). During his tenure, he created a global team and was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-amplifying mRNA vaccines.